Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The First Sporadic Creutzfeldt-Jakob Disease Case with a Rare Molecular Subtype VV1 and 1-Octapeptide Repeat Deletion in PRNP

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Focal Epithelial Hyperplasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Human Papillomavirus Related Neoplasia of the Ocular Adnexa

    Research output: Contribution to journalReviewResearchpeer-review

  1. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1

    Research output: Contribution to journalReviewResearchpeer-review

  5. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 µM, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.

Original languageEnglish
Article number2082
JournalViruses
Volume13
Issue number10
Pages (from-to)1-11
Number of pages11
ISSN1999-4915
DOIs
Publication statusPublished - 15 Oct 2021

    Research areas

  • Adamantane, Antiviral, Barrier to escape, Combination treatment, COVID-19, Drug repurposing, Hepatitis C virus p7 inhibitor, Ion-channel inhibitor, Remdesivir, SARS-CoV-2

ID: 68561622